NextCell Pharma AB (NXTCL.ST)
SEK 1.14
(7.17%)
SEK 1.14
(7.17%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | -576.01 Thousand SEK | -101.44% |
| 2023 | 40.11 Million SEK | 214.32% |
| 2022 | 12.76 Million SEK | 22.91% |
| 2021 | 10.38 Million SEK | 41.69% |
| 2020 | 7.32 Million SEK | -1.53% |
| 2019 | 7.44 Million SEK | 26.73% |
| 2018 | 5.87 Million SEK | -44.53% |
| 2017 | 10.58 Million SEK | 66.39% |
| 2016 | 6.36 Million SEK | 18.27% |
| 2015 | 5.38 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q4 | - SEK | -100.29% |
| 2024 Q1 | 11.74 Million SEK | 29.36% |
| 2024 Q2 | 9.97 Million SEK | -15.05% |
| 2024 Q3 | 8.74 Million SEK | -12.3% |
| 2023 Q3 | 11.5 Million SEK | 8.83% |
| 2023 Q1 | 6.82 Million SEK | 99.23% |
| 2023 FY | 40.11 Million SEK | 214.32% |
| 2023 Q4 | 9.07 Million SEK | -21.09% |
| 2023 Q2 | 10.57 Million SEK | 54.83% |
| 2022 Q3 | 3.71 Million SEK | 28.64% |
| 2022 Q1 | 2.74 Million SEK | 31.87% |
| 2022 Q2 | 2.88 Million SEK | 5.28% |
| 2022 Q4 | 3.42 Million SEK | -7.65% |
| 2022 FY | 12.76 Million SEK | 22.91% |
| 2021 Q3 | 2.92 Million SEK | -7.48% |
| 2021 FY | 10.38 Million SEK | 41.69% |
| 2021 Q1 | 2.31 Million SEK | 44.42% |
| 2021 Q2 | 3.16 Million SEK | 36.97% |
| 2021 Q4 | 2.07 Million SEK | -29.07% |
| 2020 Q4 | 1.6 Million SEK | -18.12% |
| 2020 Q3 | 1.95 Million SEK | -4.04% |
| 2020 Q2 | 2.03 Million SEK | 5.43% |
| 2020 Q1 | 1.93 Million SEK | 15.37% |
| 2020 FY | 7.32 Million SEK | -1.53% |
| 2019 Q1 | 2.09 Million SEK | 12.12% |
| 2019 FY | 7.44 Million SEK | 26.73% |
| 2019 Q3 | 1.79 Million SEK | -7.55% |
| 2019 Q4 | 1.67 Million SEK | -6.74% |
| 2019 Q2 | 1.94 Million SEK | -7.26% |
| 2018 Q4 | 1.86 Million SEK | 21.44% |
| 2018 FY | 5.87 Million SEK | -44.53% |
| 2018 Q1 | 2.65 Million SEK | -0.58% |
| 2018 Q2 | 2.47 Million SEK | -6.8% |
| 2018 Q3 | 1.53 Million SEK | -37.76% |
| 2017 Q4 | 2.66 Million SEK | -21.91% |
| 2017 Q1 | 2.29 Million SEK | 186.54% |
| 2017 Q2 | 2.13 Million SEK | -7.02% |
| 2017 Q3 | 3.41 Million SEK | 59.9% |
| 2017 FY | 10.58 Million SEK | 66.39% |
| 2016 Q1 | 2.91 Million SEK | 0.0% |
| 2016 FY | 6.36 Million SEK | 18.27% |
| 2016 Q4 | -2.65 Million SEK | -183.12% |
| 2016 Q3 | 3.19 Million SEK | 9.7% |
| 2016 Q2 | 2.91 Million SEK | -0.0% |
| 2015 FY | 5.38 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Active Biotech AB (publ) | 44.8 Million SEK | 101.285% |
| Biovica International AB (publ) | 133.72 Million SEK | 100.431% |
| Cantargia AB (publ) | 290.01 Million SEK | 100.199% |
| CombiGene AB (publ) | 44.14 Million SEK | 101.305% |
| Cyxone AB (publ) | 28.21 Million SEK | 102.042% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | 103.918% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | 102.034% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | 100.527% |
| Fluicell AB (publ) | 28.61 Million SEK | 102.013% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | 100.428% |
| Mendus AB (publ) | 129.13 Million SEK | 100.446% |
| Isofol Medical AB (publ) | 7.26 Million SEK | 107.925% |
| I-Tech AB | 40.14 Million SEK | 101.435% |
| Intervacc AB (publ) | 79.78 Million SEK | 100.722% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | 107.941% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | 100.424% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | 103.512% |
| OncoZenge AB (publ) | 15.9 Million SEK | 103.622% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | 101.351% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 100.161% |
| Lipum AB (publ) | 37.3 Million SEK | 101.544% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 100.188% |
| Ziccum AB (publ) | 27.87 Million SEK | 102.066% |
| BioArctic AB (publ) | 89.62 Million SEK | 100.643% |
| Genovis AB (publ.) | 88.19 Million SEK | 100.653% |
| Camurus AB (publ) | 1.05 Billion SEK | 100.054% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | 100.993% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | 100.693% |
| Aptahem AB (publ) | 10.01 Million SEK | 105.753% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 100.179% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | 100.317% |
| Kancera AB (publ) | 63.07 Million SEK | 100.913% |
| Saniona AB (publ) | 1.07 Million SEK | 153.484% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | 102.911% |
| AcouSort AB (publ) | 25.87 Million SEK | 102.226% |
| Xintela AB (publ) | 57.31 Million SEK | 101.005% |
| Abliva AB (publ) | 27.86 Million SEK | 102.067% |
| Karolinska Development AB (publ) | 5.51 Million SEK | 110.437% |
| Amniotics AB (publ) | 29.07 Million SEK | 101.981% |
| 2cureX AB (publ) | 36.51 Million SEK | 101.577% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | 103.931% |
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 100.038% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 100.067% |
| Biosergen AB | 26.8 Million SEK | 102.149% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | 103.257% |
| Corline Biomedical AB | 30.16 Million SEK | 101.909% |
| Nanologica AB (publ) | 69.88 Million SEK | 100.824% |
| LIDDS AB (publ) | 27.75 Million SEK | 102.076% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 100.298% |
| BioInvent International AB (publ) | 441.4 Million SEK | 100.13% |
| SynAct Pharma AB | 224.49 Million SEK | 100.257% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | 101.304% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | 102.405% |
| Alzinova AB (publ) | 36.39 Million SEK | 101.583% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | 100.519% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 100.199% |
| Pila Pharma AB (publ) | 7.85 Million SEK | 107.332% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | 100.501% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | 102.631% |
| Simris Alg AB (publ) | 38.64 Million SEK | 101.491% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | 100.403% |